A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

Targeted Oncology

Volumn 9, Issue 3, 2014, Pages 239-249

  Waldron, Nate N ^a   Barsky, Sanford H ^b   Dougherty, Phillip R ^a   Vallera, Daniel A ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cancer stem cells; CD133; EpCAM; Head and neck squamous cell carcinoma; Immunotoxins; Targeted toxins

Indexed keywords

EID: 84880656646     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0290-9     Document Type: Article

References (43)

1. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC (2007) Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am J Pathol 171:386–395
2. Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in stem cell signaling. Cancer Res 69:5627
3. Takahashi-Yanaga F, Kahn M (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16:3153–3162
4. Moncharmont C, Levy A, Gilormini M, Bertrand G, Chargari C, Alphonse G, Ardail D, Rodriguez-Lafrasse C, Magne N (2012) Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett 322:139–147
5. Van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31:1913–1921
6. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768
7. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW (1997) AC133, A novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012
8. Boman BM, Wicha MS (2008) Cancer stem cells: a step toward the cure. J Clin Oncol 26:2795–2799
9. Ferrandina G, Petrillo M, Bonanno G, Scambia G (2009) Targeting CD133 antigen in cancer. Expert Opin Ther Targets 13:823–837
10. Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26:3008–3017
11. Mak AB, Nixon AM, Kittanakom S, Stewart JM, Chen GI, Curak J, Gingras AC, Mazitschek R, Neel BG, Stagljar I, Moffat J (2012) Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. Cell Rep 2:951–963
12. Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M, Nakagawara A, Kamijo T (2011) CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 30:97–105
13. Swaminathan SK, Niu L, Waldron NN, Kalscheuer S, Zellmer D, Olin MR, Ohlfest JR, Vallera DA, Panyam J (2013) Identification and characterization of a novel scFv recognizing human and mouse CD133. Drug Deliv Transl Res. doi:10.1007/s13346-012-0099-6
14. Waldron NN, Kaufman DS, Oh S, Inde Z, Hexum MK, Ohlfest JR, Vallera DA (2011) Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol Cancer Ther 10:1829–1838
15. Ohlfest JR, Zellmer D, Panyam J, Swaminathan SK, Oh S, Waldron NN, Toma S, Vallera DA (2012) Immunotoxin targeting CD133+ breast carcinoma cells. Drug Deliv Transl Res. doi:10.1007/s13346-012-0066-2
16. Skubitz APN, Taras EP, Boylan KLM, Waldron NN, Oh, S, Panoskaltsis-Mortari A, Vallera DA (2013) Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol. doi:10.1016/j.ygyno.2013.05.027
17. Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA (2009) Design and modification of EGF4KDEL 7mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 101:1114–1123
18. Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA (2011) A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol 103:255–266
19. Vallera DA, Oh S, Chen H, Shu Y, Frankel AE (2010) Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther 9:1872–1883
20. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA (2007) Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 13:3058–3067
21. MacDonald GC, Rasamoelisolo M, Entwistle J, Cizeau J, Bosc D, Cuthbert W, Kowalski M, Spearman M, Glover N (2009) A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther 2:105–114
22. Kowalski M, Entwistle J, Cizeau J, Niforos D, Loewen S, Chapman W, MacDonald GC (2010) A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des Devel Ther 4:313–320
23. Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, Jewett MA, MacDonald GC (2012) A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with Bacillus Calmette–Guérin. J Urol 188:1712–1718
24. Fitzgerald D, Pastan I (1989) Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 81:1455–1463
25. Kreitman RJ, Pastan I (1995) Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307(697):29–37
26. Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP (2009) Genetic alteration of a bispecific ligand directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic. Leuk Res 33:1233–1242
27. Worsham MJ, Chen KM, Meduri V, Nygren AO, Errami A, Schouten JP, Benninger MS (2006) Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132:668–677
28. Abu-Ali S, Fotovati A, Shirasuna K (2008) Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers. Mol Cancer 7:47
29. Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Onc 26:2839–2845
30. Fabrizi E, di Martino S, Pelacchi F, Ricci-Vitiani L (2010) Therapeutic implications of colon cancer stem cells. World J Gastroenterol 16:3871–3877
31. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J, Gurney AL (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3:e2428
32. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, Samuel S, Kim MP, Lim SJ, Ellis LM (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69:1951–1957
33. Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH (1999) A novel human xenograft model of inflammatory breast cancer. Cancer Res 59:5079–5084
34. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148:3–15
35. Imrich S, Hachmeister M, Gires O (2012) EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr 6:30–38
36. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin L, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136:1012–1024
37. Rutella S, Bonanno G, Marone M, De Ritis D, Mariotti A, Voso MT, Scambia G, Mancuso S, Leone G, Pierelli L (2003) Identification of a novel subpopulation of human cord blood CD34–CD133− CD7–CD45þ lineage-cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. J Immunol 171:2977–2988
38. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C (2011) Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 30:4609–4621
39. Suuronen EJ, Wong S, Kapila V, Waghray G, Whitman SC, Mesana TG, Ruel M (2006) Generation of CD133+ cells from CD133− peripheral blood mononuclear cells and their properties. Cardiovasc Res 70:126–135
40. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B-cell epitopes. Proc Natl Acad Sci U S A 105(701):11311–11316
41. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J (2007) Anti-mesothelin immunotoxin SS1P in combination with Gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 13:7166–7171
42. Pearson JW, Sivam G, Manger R, Wiltrout RH, Morgan AC Jr, Longo DL (1989) Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res 49:4990–4995
43. Fujiwara S, Wada H, Miyata H, Kawada J, Kawabata R, Nishikawa H, Gnjatic S, Sedrak C, Sato E, Nakamura Y, Sakakibara M, Kanto T, Shimosegawa E, Hatazawa J, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Nakayama E, Mori M, Doki Y (2012) Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother 35(6):513–521